

Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression

NCT06510894

Status RECRUITING
Sponsor University of Pennsylvania
Enrollment 40 participants

Key Eligibility Criteria

Inclusion (4)

- Adult patients, at least 18 years of age
- No history of cardiovascular disease, including hypertension, hyperlipidemia, diabetes mellitus, heart failure, coronary artery disease, cardiac surgery, arrhythmias per medical record review and/or self-report
- No history of chronic liver or kidney disease per medical record review and/or self-report.
- Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion (5)

- Females who are pregnant or breast-feeding will not be eligible for this study. Female participants of child-bearing potential will have a urine pregnancy test during the screening visit and prior to FDG injection.
- Participants who are currently taking diuretics for any indication.
- Participants with an eGFR level <30 mL/min/1.73m².
- Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.
- Any other medical or psychological condition that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.

Locations (1 total)

University of Pennsylvania, Philadelphia, Pennsylvania, United States